Skip to main content
. Author manuscript; available in PMC: 2021 Sep 22.
Published in final edited form as: Mol Cancer Res. 2020 Feb 6;18(5):774–786. doi: 10.1158/1541-7786.MCR-18-1370

Figure 6.

Figure 6.

Dasatinib affects viability of GBM cells with elevated c-Src activity but not normal cells with negligible Src activity. A, Human-derived GBM cell lines or NHAs were lysed and protein lysates were immunoblotted with indicated antibodies. B, Tumors or unaffected normal brains obtained from intracranial U87 xenograft from two different mice were lysed and protein lysates were immunoblotted with indicated antibodies. C, GSCs or NSCs were lysed and protein lysates were immunoblotted with indicated antibodies. D, Human operative GBM samples or normal derived brains (NB) were lysed and immunoblotted with indicated antibodies. E, GL261 cells or normal mouse astrocytes were lysed and protein lysates were immunoblotted with indicated antibodies. F, Equal number of GL261 cells were plated and treated with or without indicated concentrations of dasatinib and cell viability was assessed by an Alamar blue assay. Data represent mean ± SEM of three independent experiments performed in octuplet. *, P < 0.05 Student t test compared with control. G, Equal number of U87 or NHAs treated with or without indicated concentrations of dasatinib was plated and cell viability was assessed by an Alamar blue assay. Data represent mean ± SEM of three independent experiments performed in octuplet. *, P < 0.05 Student t test compared with control. H, Equal number of GSC 7-2, GSC 8–11, or NSCs treated with or without indicated concentrations of dasatinib were plated and cell viability was assessed by an Alamar blue assay. Data represent mean ± SEM of three independent experiments performed in octuplet. *, P < 0.05 Student t test compared with control. I, GL261, U87, or GSC 7-2 treated with or without dasatinib 100 nmol/L were lysed and immunoblotted with indicated antibodies. GL261 (J), U87 (K), or GSC 7-2 (L) control or stably expressing FLAG-CIC(WT or Y1455F) treated with or without indicated concentrations of dasatinib were plated and cell viability was assessed by an Alamar blue assay. Data represent mean ± SEM of three independent experiments performed in octuplet. *, P < 0.05 Student t test compared with respective controls.